Chlorozotocin

Chlorozotocin

SCHEMBL8539

O=NN(CCCl)C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
KDM4E B2RXH2 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C19 P33261 1/20 0.64
ADRA2A P08913 2/20 0.47
PDE4A P27815 1/20 0.47
ADRA1A P35348 1/20 0.47
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.42
ABCB11 O95342 1/20 0.42
GSR P00390 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
KMT2A Q03164 1/20 0.42
HK2 P52789 5/20 0.42
HK1 P19367 4/20 0.42
PYGB P11216 6/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorozotocin SCHEMBL1648834 1.00 LMNA (0.64) LMNAKDM4ECYP2D6CYP2C19ADRA2A
Chlorozotocin SCHEMBL11409480 1.00 LMNA (0.64) LMNAKDM4ECYP2D6CYP2C19ADRA2A
Chlorozotocin SCHEMBL11409484 1.00 LMNA (0.64) LMNAKDM4ECYP2D6CYP2C19ADRA2A
Chlorozotocin SCHEMBL19520816 0.99 LMNA (0.63) LMNAKDM4ECYP2D6CYP2C19ADRA2A
Chlorozotocin SCHEMBL10424026 0.93 LMNA (0.78) LMNAKDM4ECYP2D6CYP2C19ADRA2A
SCHEMBL11573190 0.91 LMNA (0.52) LMNAKDM4ECYP2D6CYP2C19ADRA2A
SCHEMBL29572633 0.91 LMNA (0.52) LMNAKDM4ECYP2D6CYP2C19ADRA2A
SCHEMBL11573181 0.91 LMNA (0.52) LMNAKDM4ECYP2D6CYP2C19ADRA2A
SCHEMBL11777948 0.89 LMNA (0.50) LMNAKDM4ECYP2D6CYP2C19ADRA2A
SCHEMBL13382542 0.87 LMNA (0.64) LMNAKDM4ECYP2D6CYP2C19HK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 25956 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260085100-A1 METHODS OF ANTIGEN PRODUCTION THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2026-03-26 US claimed
EP-4710918-A1 OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) 2026-03-18 EP claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4698185-A1 METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES Osasuna Therapeutics SA (CH) 2026-02-25 EP claimed
EP-4694909-A1 METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION RS Oncology, LLC (US) 2026-02-18 EP claimed
EP-4687999-A1 TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS OBI Pharma, Inc. (TW) 2026-02-11 EP claimed
EP-0977725-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 2000-02-09 EP claimed
WO-1999058126-A1 USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 1999-11-18 WO claimed
WO-1999042578-A2 MODULATION OF CELL PROLIFERATION, METHODS AND REAGENTS COLD SPRING HARBOR LABORATORY (US) 1999-08-26 WO claimed
WO-1999001118-A9 ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS ATHEROGENICS INC (US) 1999-05-20 WO claimed
WO-1999001118-A2 ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS ATHEROGENICS, INC. (US) 1999-01-14 WO claimed
WO-1998032718-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 1998-07-30 WO claimed
EP-0758249-A1 PROGRAMMABLE GENOTOXIC AGENTS AND USES THEREFOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1997-02-19 EP claimed
WO-1995030442-A1 PROGRAMMABLE GENOTOXIC AGENTS AND USES THEREFOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1995-11-16 WO claimed
EP-0359347-B1 COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING NEORX CORPORATION (US) 1992-12-23 EP claimed
EP-0359347-A2 Covalently-linked complexes and methods for enhanced cytotoxicity and imaging NEORX CORPORATION (US) 1990-03-21 EP claimed